Cite
Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial.
MLA
Schmitz, Joy M., et al. “Targeting White Matter Neuroprotection as a Relapse Prevention Strategy for Treatment of Cocaine Use Disorder: Design of a Mechanism-Focused Randomized Clinical Trial.” Contemporary Clinical Trials, vol. 111, Dec. 2021, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.cct.2021.106603.
APA
Schmitz, J. M., Lane, S. D., Weaver, M. F., Narayana, P. A., Hasan, K. M., Russell, D. D., Suchting, R., & Green, C. E. (2021). Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial. Contemporary Clinical Trials, 111, N.PAG. https://doi.org/10.1016/j.cct.2021.106603
Chicago
Schmitz, Joy M., Scott D. Lane, Michael F. Weaver, Ponnada A. Narayana, Khader M. Hasan, DeLisa D. Russell, Robert Suchting, and Charles E. Green. 2021. “Targeting White Matter Neuroprotection as a Relapse Prevention Strategy for Treatment of Cocaine Use Disorder: Design of a Mechanism-Focused Randomized Clinical Trial.” Contemporary Clinical Trials 111 (December): N.PAG. doi:10.1016/j.cct.2021.106603.